{
  "id": "e524b82e-ab92-460a-afb6-634eeb9ea583",
  "patient_id": "bc8a3bb5-01b7-4bbd-a79a-43f812620f3a",
  "encounter_id": "5f9f4650-7af0-451a-813d-6693489bdc44",
  "analysis_type": "Genetic Testing Recommendation",
  "input_text": "Patient: Steven Ortega, DOB: 2006-02-16, Gender: Male\n\nChief Complaint: headache\n\nS: Patient Describes no history of illness\n\nO: No physical exam documented.\n\nA: No assessment documented.\n\nP: No plan documented.\n\n--- IMAGING & SCANS ---\n- ECG (3/25/2025): ECG Scan for Patient\n\n--- IMAGING & SCANS ANALYSIS ---\n\n[Scan 1: ECG (2025-03-25T09:09:28.833517)]\nFile: norm.png\nDescription: ECG Scan for Patient\nAnalysis: Okay, let's analyze this ECG tracing. Here\u2019s a detailed breakdown of what I observe, considering it's an ECG scan for a patient:\n\n**Overall Impression:**\n\nThis ECG shows a sinus rhythm, but with several concerning features that warrant careful attention. The primary concern is the presence of significant left ventricular hypertrophy (LVH). \n\n**Detailed Observations:**\n\n1. **Rate:** The heart rate appears to be approximately 75-80 beats per minute. It's regular, which is good.\n\n2. **Rhythm:** The rhythm is sinus rhythm \u2013 the P waves appear to be originating from the sinoatrial node, the heart\u2019s natural pacemaker.\n\n3. **P Waves:** \n   *  Generally, P waves are upright in leads I, II, aVF, and V1-V3, indicating normal atrial depolarization. \n   *  However, they are slightly bizarre and not perfectly consistent in morphology.\n\n4. **PR Interval:** The PR intervals are generally within the normal range (0.12-0.20 seconds). \n\n5. **QRS Complex:** This is where the most significant abnormalities are observed.\n   * **Width:** The QRS complexes are wide \u2013 consistently greater than 0.12 seconds. This is a key indicator of intraventricular conduction delay.\n   * **Morphology:** The QRS complexes are notched, particularly in V1, V3, V5, and V6. This suggests a ventricular depolarization abnormality, possibly due to the LVH. The R waves are also prominent and elevated, further supporting this.\n\n6. **ST Segment & T Waves:**\n   * **ST Segment:** The ST segments are generally isoelectric (flat) except for a slight depression in leads V4-V6. This could represent early signs of ischemia or myocardial strain, but needs further investigation.\n   * **T Waves:** The T waves are predominantly negative, which is a common finding in LVH.\n\n7. **Axis:** The QRS axis appears to be shifted to the left (approximately -45\u00b0 to -60\u00b0), which is consistent with LVH.\n\n8. **Intervals:**\n   * **QT Interval:** The QT interval is within the normal range.\n\n**Significant Findings & Potential Abnormalities:**\n\n* **Left Ventricular Hypertrophy (LVH):** This is the most prominent finding. The wide QRS complexes, prominent\n\n\n--- MEDICAL ENTITY ANALYSIS ---\n\nHISTORY: -02-16, illness\nSIGN_SYMPTOM: headache, P waves, depolarization, intraventricular conduction delay, depression, Left Ventricular\nDIAGNOSTIC_PROCEDURE: physical exam, assessment, ECG, heart rate, Rhythm, rhythm, P Waves, P waves, leads, atrial, PR Interval, PR intervals, QRS Complex, QRS complexes, R waves, ST Segment, T Waves, ST segments, T waves, Axis, QRS axis, Intervals, QT Interval, QT interval\nDATE: 03, 25, 09:09:28.833\nLAB_VALUE: sinus rhythm, 75-80 beats per minute, regular, upright, normal, slightly bizarre, not, consistent, within the normal range, 0.12-0.20 seconds, wide, greater than 0.12 seconds, notched, prominent, elevated, isoelectric, flat, negative, shifted to the left, -45\u00b0 to -60\u00b0, within, normal range\nSEVERITY: significant\nDISEASE_DISORDER: left ventricular hypertrophy, LVH, ventricular depolarization abnormality, ischemia, myocardial strain, Hypertrophy, H\nBIOLOGICAL_STRUCTURE: sinoatrial node, V1, V3, V5, and V6\nDETAILED_DESCRIPTION: natural pacemaker, I, II, aVF, and V1-V3, ,, V4-V6",
  "recommendation": "Unknown",
  "reasoning": "The ECG shows significant left ventricular hypertrophy (LVH), a prominent finding.  The wide QRS complexes, prominent R waves, and negative T waves all support this diagnosis.  While the patient's chief complaint is only a headache and there is no documented physical exam or assessment, the ECG findings are highly suggestive of a serious underlying cardiac condition.  The literature review reveals several conditions associated with LVH, including hypertrophic cardiomyopathy (HCM). HCM is often diagnosed during adolescence or young adulthood and can present with a range of symptoms, including shortness of breath, chest pain, palpitations, and even sudden cardiac death.  Given the significant LVH observed in the ECG, genetic testing for HCM is strongly recommended to identify any underlying genetic mutations that may be contributing to this condition.  This testing would allow for appropriate management and risk assessment for the patient and his family.  Other conditions like Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) and Long QT Syndrome (LQTS) are also possibilities, but the ECG findings point more strongly towards HCM.  Further investigation, including a thorough physical examination and potentially additional cardiac imaging (echocardiogram), is necessary to rule out other conditions and to fully assess the patient's cardiac status.",
  "confidence": "75%",
  "model_used": "Gemini-Pro",
  "retrieved_docs": [
    {
      "id": "cvt_txt_3",
      "contents": "\u2022 History of exercise- or emotion-related palpitations and dizziness in some individuals   \n\u2022 Sudden unexpected cardiac death triggered by acute emotional stress or exercise   \n\u2022 Family history of juvenile sudden cardiac death triggered by exercise or acute emotion   \n\u2022 Exercise-induced bidirectional or polymorphic ventricular arrhythmias \u26ac EKG during a graded exercise (exercise stress test) \\* allows ventricular arrhythmias to be reproducibly elicited in the majority of afected individuals. Typically, the onset of ventricular arrhythmias is 90-120 beats per minute. \u26ac With increase in workload, the complexity of arrhythmias progressively increases from isolated premature beats to bigeminy and runs of non-sustained ventricular tachycardia (VT). If the afecte d individual continues exercising, the duration of the runs of VT progressively increases and VT may become sustained. \u26ac An alternating $180^{\\circ}$ -QRS axis on a beat-to-beat basis, so-called bidirectional VT, is ofen the distinguishing presentation of CPVT arrhythmias [Priori et al 2021]. \u26ac Notably, some individuals with CPVT may also present with irregular polymorphic VT without a \"stable\" QRS vector alternans [Swan et al 1999, Priori et al 2002]. \u26ac Exercise-induced supraventricular arrhythmias (supraventricular tachycardia and atrial fbrillatio n) are common [Leenhardt et al 1995, Fisher et al 1999]. \n\u2022 Ventricular fbrillation occurring in the setting of acute stress \\* Note: Te resting EKG of individuals with CPVT is usually normal. Some authors have reported a lower-thannormal resting heart rate [Postma et al 2005] and others have observed a high incidence of prominent U waves, particularly in the precordial leads [Leenhardt et al 1995, Aizawa et al 2006]. Overall, these features are inconsistent and not sufciently specifc to allow diagnosis. Terefore, in many instances the origin of the syncope may be erroneously attributed to a neurologic disorder. Te exercise stress test is the single most important diagnostic test.",
      "token_count": 485,
      "sentence_count": 15
    },
    {
      "id": "rws_txt_7",
      "contents": "stablishing a specifc genetic cause of long QT syndrome (LQ \u2022 Can aid in discussions of prognosis (which are beyond the scope of this GeneReview) and genetic counseling; \u2022 Usually involves a medical history, physical examination, family history, and genomic/genetic testing. \n\nClinical history. Clinical history in individuals with syncope or a cardiac arrest can reveal specifc triggers for the cardiac event that can be gene specifc. On rare occasions LQTS is accompanied by gene-spe cifc extracardiac features. \nPhysical examination. Te great majority of individuals with LQTS do not have associated physical features. On rare occasions, LQTS is accompanied by gene-specifc extracardiac features. Individuals with EKG characteristics suggestive of a specifc LQTS-associated syndrome (e.g., EKG with T-U patterns characteristic of Andersen-Tawil syndrome) can be assessed for physical features of that syndrome. \nFamily history. A three-generation family history should be taken, with attention to relatives with manifestations of LQTS \u2013 including syncope, aborted cardiac arrest, or sudden death in a child or (young) adult \u2013 and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing and EKG recordings. Specifc focus should also be on triggers of events in relatives, as well as epilepsy (LQTS-associated syncopes may have been attributed to epilepsy). In such instances, review of medical records should include EEG recordings, accompanied by an EKG, which can show QTc prolongation in afected family members. \nEKG evaluation. Te corrected QT (QTc) values on resting EKG and ST-T wave morphology can suggest a specifc genetic cause of LQTS (see Table 2). Additional tests can be helpful to unmask QTc prolongation in individuals with borderline QTc values on resting EKG [Priori et al 2013]: \n\u2022 Exercise EKG, which commonly shows failure of the QTc to shorten normally and even prolongation of the QTc interval [Jervell & Lange-Nielsen 1957, Vincent et al 1991, Swan et al 1998, Horner et al 2011, Sy et al 2011].",
      "token_count": 484,
      "sentence_count": 17
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_754",
      "contents": " C-25) in the absence of predisposing cardiac conditions (e.g., aortic stenosis) or cardiovascular conditions (e.g., longstanding hypertension). The clinical manifestations of HCM range from asymptomatic to progressive heart failure to sudden cardiac death and vary from individual to individual even within the same family. Common symptoms include shortness of breath (particularly with exertion), chest pain, palpitations, orthostasis, presyncope, and syncope. Most often the LVH of HCM becomes apparent during adolescence or young adulthood, although it may also develop late in life, in infancy, or in childhood. \n\nManagement \nBefore identification of the genes responsible for HCM, diagnosis of HCM could only be made through integration of examination, electrocardiogram, echocardiogram, and invasive angiographic/hemodynamic studies, disproportionately identifying patients with left ventricular outflow obstruction. Genetic testing for HCM is now available and can provide important insights into family management by definitively identifying at-risk relatives (i.e., those who have inherited the family\u2019s pathogenic mutation). Mutations found are considered pathogenic based on the following criteria: (1) cosegregation with the HCM phenotype in family members; (2) previously reported or identified as a cause of HCM; (3) absent from unrelated and ethnic-matched normal controls; (4) important alteration in protein structure and function; and (5) amino acid sequence change in a region of the protein otherwise highly conserved through evolution. However, even with the use of these criteria, a considerable number of variants are classified as VUSs (see Chapter 16), making the test results ambiguous. \nBecause diagnosis and sudden cardiac death risk are both linked to the presence of LVH and because the penetrance of LVH is age-dependent, clinical evaluation must continue longitudinally. Screening is annual during adolescence and early adulthood when LVH most commonly emerges. Early childhood screening is appropriate if there is a family history of early-onset disease or other concerns. During adulthood, screening is recommended approximately every $5$ years or in response to clinical changes because LVH can develop late in life.",
      "token_count": 473,
      "sentence_count": 15
    },
    {
      "id": "myotonia-c_txt_19",
      "contents": "Author History \n",
      "token_count": 2,
      "sentence_count": 1
    },
    {
      "id": "arvd_txt_9",
      "contents": "Molecular genetic testing is recommended in individuals who both fulfll diagnostic criteria as well as those with suspected arrhythmogenic right ventricular cardiomyopathy (ARVC) to (1) confrm the diagnosis of ARVC, as identifcation of an ARVC-related pathogenic variant is a major diagnostic criteria in the 2010 Task Force Criteria [Marcus et al 2010]; (2) guide management in those with more than one ARVC-related pathogenic variant identifed [Towbin et al 2019, James et al 2021]; and (3) enable testing of at-risk relatives (see Genetic Risk Assessment and Surveillance for Cardiac Involvement). \nNote: American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of ventricular arrhythmias and prevention of sudden cardiac death recommend genetic counseling and molecular genetic testing for individuals with clinically diagnosed or suspected ARVC as a class IIa recommendation (i.e., a moderate level of evidence supports the recommendation is reasonable, can be useful/efective/benefcial, and the benefts outweigh the risks) [Al-Khatib et al 2018]. \nEstablishing the specifc genetic cause of ARVC usually involves an evaluation with a cardiologist including medical history, physical examination, cardiology assessment, family history, and molecular genetic testing. Note: Molecular genetic testing should begin with a proband with a clinical diagnosis of ARVC or suspected ARVC rather than an unafected family member; molecular testing of an afected individual will provide the most informative results [James et al 2021]. \nMedical Evaluation \nMedical history and physical examination are directed at identifying physical features associated with spe cifc genetic causes of ARVC (Table 1). \nCardiology evaluation includes imaging to visualize the right ventricle, stress testing, and telemetric cardiac rhythm monitoring, as dictated by personal and family history. \nFamily history should include a three-generation family history with attention to heart palpitations, syncope, and sudden death in relatives; and documentation of relevant fndings through direct examination or review of medical records, including results of molecular genetic testing, cardiovascular and physical examinations, and postmortem examination.",
      "token_count": 472,
      "sentence_count": 9
    },
    {
      "id": "hyper-card_txt_12",
      "contents": " Clinical cardiovascular screening by physical examination, EKG, and echocardiography should be performed in accordance with published recommendations [Ommen et al 2020] in all asymptomatic frst-degre e relatives (adults and children) of an individual with HCM in whom a pathogenic variant has not been identife d (see Table 4b). \n\nBecause penetrance of diagnostic features (i.e., LVH) is age dependent, a single unremarkable evaluation does not exclude the possibility of future development of HCM. Diagnostic clinical manifestations are ofen not present in infancy / early childhood; they commonly develop during adolescence and early adulthood, but may also develop late in life. Terefore, longitudinal follow up is required at a frequency based on the individual's age and family history and physician discretion. Screening should be performed in response to any symptoms that develop or any change in clinical status. \nNote: As understanding of human DNA variation evolves, it is possible that the classifcation of a variant will change, potentially afecting the recommendations made to a person/family. It is recommended that families of individuals with HCM follow up with a cardiovascular genetics clinic and/or genetic counselor on a regular basis as genetic testing methods improve. \nResources \nGeneReviews staf has selected the following disease-specifc and/or umbrella support organizations and/or registries for the beneft of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here. \nChildren's Cardiomyopathy Foundation Phone: 866-808-2873 (toll-free) Fax: 201-227-7016 Email: info@childrenscardiomyopathy.org www.childrenscardiomyopathy.org \nHypertrophic Cardiomyopathy Association (HCMA)   \n328 Green Pond Road   \nPO Box 306   \nHibernia NJ 07842   \nPhone: 973-983-7429   \nFax: 973-983-7870   \nEmail: support@4hcm.org \nwww.4hcm.org \nAmerican Heart Association (AHA)   \n7272 Greenville Avenue   \nDallas TX 75231   \nPhone: 800-242-8721 (toll-free)   \nEmail: review.personal.info@heart.org   \n",
      "token_count": 482,
      "sentence_count": 24
    },
    {
      "id": "salih-myo_txt_1",
      "contents": "Agents/circumstances to avoid: Ibuprofen in those with congestive heart failure. \nGenetic counseling \nSalih myopathy is inherited in an autosomal recessive manner. Te parents of an afected child are obligate heterozygotes (i.e., carriers of one pathogenic variant) and are asymptomatic. At conception, each sib of an afected individual has a $25\\%$ chance of being afected, a $50\\%$ chance of being an asymptomatic carrier, and a $25\\%$ chance of being unafected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family have been identifed. \nDiagnosis \nSuggestive Findings \nSalih myopathy should be suspected in individuals with the following clinical, laboratory, electrophysiologic, imaging, and histopathology fndings. \nClinical \n\u2022 Muscle weakness manifesting during the neonatal period or in early infancy   \n\u2022 Delayed motor milestones but normal cognitive development   \n\u2022 Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy   \n\u2022 Development of dilated cardiomyopathy between ages fve and 16 years   \n\u2022 Major heart rhythm disturbances leading to sudden death before age 20 years \nm creatine kinase (CK) is marginally to moderately increase \nElectrophysiologic \n\u2022 Electrocardiography. Lef axis deviation (lef anterior fascicular block) can be seen as early as age four years (Figure 1). With the onset of dilated cardiomyopathy, rhythm disturbances can include polymorphic premature ventricular complexes, bigeminism and trigeminism, couplets, triplets, atrioventricular heart block, atrioventricular nodal reentrant tachycardia, premature atrial complexes, premature ventricular complexes, and ventricular tachycardia.   \n\u2022 Electromyography shows myopathic features (low-amplitude polyphasic potentials of short duration).   \n\u2022 Nerve conduction studies are normal. \n",
      "token_count": 452,
      "sentence_count": 21
    },
    {
      "id": "arvd_txt_19",
      "contents": " A study in younger individuals suggested that cardiac MRI was more sensitive than echocardiogram but that it was still unusual, even with cardiac MRI, to identify ARVC in children before age ten years [Etoom et al 2015]. \nIn children younger than age 18 years. Te 2010 Task Force Criteria [Marcus et al 2010] should be used with caution, as many of the EKG diagnostic criteria are a normal fnding in children, such as inverted T waves in right precordial leads (V1, V2, and V3) [Te Riele et al 2021]. Cardiac MRI has been shown to have a better positive predictive value (and especially data from echocardiogram and cardiac MRI combined) [Steinmetz et al 2018, Te Riele et al 2021]. \nRecommendations for Medical and Surgical Management of ARVC \nAfected individuals should be monitored by a cardiologist who is knowledgeable about ARVC. Management of individuals with ARVC is complicated by its variable course and the limited specifcity of clinical fndings to predict arrhythmia risk. Management should be individualized and based on the specifc results of detailed clinical and genetic investigation. \nGene-Specific Management Recommendations \nDSP. Because of the risk of lef ventricular dysfunction associated with $D S P$ pathogenic variants [Smith et al 2020], management for individuals with $D S P$ -related ARVC should address monitoring and management for  lef ventricular dysfunction, including guideline-directed therapy [Towbin et al 2019, Heidenreich et al 2022]. \nGeneral Management Recommendations for ARVC \nTreatment recommendations for ARVC can be found in an international task force consensus statement [Corrado et al 2015]. Additional guidance is found in the American College of Cardiology / American Heart Association / Heart Rhythm Society (AHA/ACC/HRS) guideline for management of individuals with ventricular arrhythmias and the prevention of sudden cardiac death [Al-Khatib et al 2018] and in an updated Heart Rhythm Society guideline for arrhythmogenic cardiomyopathy [Towbin et al 2019]. \n\u2022 Management is focused on prevention of syncope, cardiac arrest, and sudden death (see Prevention of Primary Manifestations).   \n",
      "token_count": 470,
      "sentence_count": 14
    },
    {
      "id": "barth_txt_9",
      "contents": " Spencer et al [2006] observed that with standard cardiac medications for dilated cardiomyopathy more than 16/30 afected males had normal ejection fraction and lef ventricular diastolic volume. However, some responded to therapy initially but deteriorated afer a period of stability, requiring cardiac transplantation [Adwani et al 1997, Mangat et al 2007]. \nArrhythmia. Te risk for arrhythmia (including supraventricular and ventricular tachycardia) and sudden death is increased. While arrhythmia has been most ofen reported in adolescents and young adults, it can occur in children of all ages. EKG abnormalities can include repolarization abnormalities and prolonged QTc intervals. \nAll 20 afected males with EKGs in the French cohort had a normal sinus rhythm. Repolarization abnormalities (including ST fattening and T-wave inversion) were seen in 17. Five had QTc values within the normal range (QTc ${<}420\\;\\mathrm{ms}_{}$ ), and fve had QTc greater than $460\\:\\mathrm{ms}$ . Te median QTc was $440\\:\\mathrm{ms}$ (range: $360{-}530~\\mathrm{ms})$ ). In the study by Kang et al [2016], nine of 21 afected individuals had prolonged QTc of greater than $460~\\mathrm{ms}$ and three had borderline QTc prolongation between 450 and $460~\\mathrm{ms}$ . \nIn fve instances of ventricular arrhythmia leading to cardiac arrest or placement of an internal defbrillato r [Spencer et al 2005]: \n\u2022 All fve individuals had normal QTc intervals;   \n\u2022 All fve had a history of recurrent vasovagal symptoms including postural dizziness, nausea, and pallor suggestive of autonomic instability;   \n\u2022 Four had only mild LV dilatation and low normal to mildly depressed LV function; only one had poor but stable LV function prior to cardiac arrest;   \n\u2022 Tree showed inducible ventricular arrhythmias on electrophysiologic testing;   \n",
      "token_count": 479,
      "sentence_count": 15
    },
    {
      "id": "rws_txt_41",
      "contents": "Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187\u201394. PubMed PMID: 22042885.   \nTardo DT, Peck M, Subbiah RN, Vandenberg JI, Hill AP. Te diagnostic role of T wave morphology biomarkers in congenital and acquired long QT syndrome: a systematic review. Ann Noninvasive Electrocardiol. 2023;28:e13015. PubMed PMID: 36345173.   \nTester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507\u201317.",
      "token_count": 241,
      "sentence_count": 14
    },
    {
      "id": "dcm-ov_txt_9",
      "contents": " Molecular genetic testing is recommended for parents, sibs, ofspring, and other at-risk family members in order to clarify their genetic status. \nTose identifed as having a familial DCM-related pathogenic variant have an increased lifetime risk for DCM and, when asymptomatic, should undergo cardiovascular clinical screening at intervals based on the individual's age [Hershberger et al 2018]. \nNote: Asymptomatic at-risk relatives who do not meet criteria for DCM (with other causes ruled out) may represent early DCM when echocardiogram results are ambiguous (e.g., lef ventricular enlargement with normal systolic function, decreased ejection fraction but normal-sized lef ventricle) and/or echocardiogram results are normal but EKG results are abnormal (e.g., signifcant conduction system disease and/or arrhythmias). \nIn general, family members without the DCM-related pathogenic variant identifed in the proband are no longer considered to be at increased risk for DCM and thus may be discharged from cardiac surveillance. However, because multiple variants in DCM-associated genes have been observed in individuals with nonsyndromic DCM [Morales et al 2020] and because families may segregate pathogenic variants in more than one DCM-related gene [Liu et al 2015, Cowan et al 2018], thorough individualized risk assessment through clinical, genetic, and family history analysis is warranted to determine if discharge from high-risk cardiac surveillance is appropriate. \nIf the Specific Genetic Cause of DCM in the Proband Has Not Been Identified \nSee Figure 1, orange box (\"Pathogenic variant not identifed\"). Perform cardiovascular screening on asymptomatic at-risk family members at intervals based on the individual's age [Hershberger et al 2018]. \nNote: Asymptomatic at-risk relatives who do not meet criteria for DCM (with other causes ruled out) may represent early DCM when echocardiogram results are ambiguous (e.g., lef ventricular enlargement with normal systolic function, decreased ejection fraction but normal-sized lef ventricle) and/or echocardiogram \n",
      "token_count": 488,
      "sentence_count": 12
    },
    {
      "id": "jln_txt_15",
      "contents": "Therapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nOther \nFamily members of individuals with JLNS should be trained in cardiopulmonary resuscitation (CPR) as up to $95\\%$ of individuals with JLNS have a cardiac event before adulthood [Schwartz et al 2006]. \nAfected individuals should wear an ID bracelet explaining their diagnosis. \nIt is appropriate to notify local emergency medical services (EMS) of high-risk persons, including those with JLNS [Hazinski et al 2004]. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nJervell and Lange-Nielsen syndrome (JLNS) is inherited in an autosomal recessive manner. \nRisk to Family Members \nParents of a proband \n\u2022 Parents of a child with JLNS are usually obligate heterozygotes (i.e., carriers of one KCNQ1 or KCNE1 pathogenic variant). In rare cases, only one parent is heterozygous and the other pathogenic variant in the proband is de novo [Schwartz et al 2000].   \n\u2022 Parents may or may not have the long QT syndrome (LQTS) phenotype. Studies have documented autosomal dominant inheritance of moderately prolonged QTc intervals in some, but not all, families in which one or more sibs have JLNS [Splawski et al 1997].   \n\u2022 Recommendations for evaluation of the parents of a child with JLNS include: \u26ac Molecular genetic testing if the pathogenic variants have been identifed; \u26ac Comprehensive electrocardiographic testing for evidence of QTc prolongation by a physician familiar with LQTS. \nSibs of a proband \n",
      "token_count": 482,
      "sentence_count": 21
    },
    {
      "id": "dcm-lmna_txt_0",
      "contents": "LMNA-Related Dilated Cardiomyopathy \nRay E Hershberger, ${\\mathsf{M D}}^{1}$ and Elizabeth Jordan, MMSc, CGC2 Created: June 12, 2008; Updated: March 17, 2022. \nSummary \nClinical characteristics \nLMNA-related dilated cardiomyopathy (DCM) is characterized by lef ventricular enlargement and/or reduced systolic function preceded (sometimes by many years) by or accompanied by conduction system disease and/or arrhythmias. LMNA-related DCM usually presents in early to mid-adulthood with symptomatic conduction system disease or arrhythmias, or with symptomatic DCM including heart failure or embolus from a  lef ventricular mural thrombus. Sudden cardiac death can occur, and in some instances is the presenting manifestation; sudden cardiac death may occur with minimal or no systolic dysfunction. \nDiagnosis/testing \nTe diagnosis of LMNA-related DCM is established in a proband with suggestive fndings and a heterozygous pathogenic variant in LMNA identifed by molecular genetic testing. \nManagement \nTreatment of manifestations: Chronic atrial fbrillation is treated initially with attempts to restore normal sinus rhythm, anticoagulation, and rate control. Symptomatic supraventricular arrhythmias are usually treated with pharmacologic therapy or ablation; symptomatic bradyarrhythmias or signifcant heart block is treated with an electronic pacemaker. Symptomatic ventricular arrhythmias, ventricular tachycardia, ventricular fbrillation, and resuscitated sudden cardiac death are treated with an implantable cardioverter defbrillator (ICD) and drug therapy as needed. Because risk for sudden cardiac death in LMNA-related DCM accompanies heart block and bradyarrhythmias, ICD use (rather than just pacemaker use) has been recommended for all indications. Treatment of symptomatic DCM, including heart failure, is pharmacologic with ACE inhibitors, beta blockers, and other conventional approaches. Progressive deterioration in lef ventricular function is treated with an ICD.",
      "token_count": 491,
      "sentence_count": 14
    },
    {
      "id": "dcm-lmna_txt_10",
      "contents": "Drugs aimed at reducing mitogen-activated protein (MAP) kinase signaling, a mechanism which has been shown to be increased in LMNA-associated DCM, are actively under investigation (ClinicalTrials.gov ident ifer NCT02351856) [Wu et al 2011, MacRae et al 2016]. \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nLMNA-related dilated cardiomyopathy (DCM) is inherited in an autosomal dominant manner. \nRisk to Family Members \nParents of a proband \n\u2022 Some individuals diagnosed with LMNA-related DCM have an afected parent. \nNote: Both sides of the family should be considered as possibly contributing. Families with DCM in both maternal and paternal lineages have been described [Liu et al 2015, Cowan et al 2018], and experience has shown that regardless of an apparent inheritance pattern in a family, assumptions regarding maternal or paternal inheritance of pathogenic variants in genes causing familial DCM in a given family may be unreliable and potentially misleading. \n\u2022 Some individuals diagnosed with LMNA-related DCM have the disorder as the result of a de novo pathogenic variant. Te proportion of individuals with LMNA-related DCM caused by a de novo pathogenic variant is unknown. \n\u2022 Recommendations for the evaluation of reportedly unafected parents of a proband include: \n\u26ac Review of medical history, physical examination, echocardiogram, and EKG to determine if a parent has detectable DCM and/or conduction system disease. Evaluation of parents may determine that one is afected but has previously escaped diagnosis possibly because of a milder phenotypic presentation (e.g.",
      "token_count": 479,
      "sentence_count": 20
    },
    {
      "id": "rws_txt_1",
      "contents": " Tis idea is incorporated in the LQTS diagnostic scoring system proposed in the European Society of Cardiology guidelines for management of LQTS [Zeppenfeld et al 2022] (see Table 1). A LQTS risk score of $>\\!3.0$ in the absence of a secondary cause for QT prolongation is sufcient for a diagnosis of LQTS. \nCardiac Features \nT wave abnormalities include T wave alternans, notched T wave, broad-based and fattened T waves (see Adler et al [2020] and Wilde et al [2022] for concise examples and Tardo et al [2023] for a comprehensive review) and are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is \nusually self-terminating and may cause palpitations, dizziness, or syncope, the most common symptom in individuals with LQTS. Syncope is typically precipitous and without warning. A careful evaluation of medical history can help distinguish LQTS-associated syncope from common vasovagal and orthostatic forms of syncope in which presyncope and other warning symptoms occur. Absence of aura, incontinence, and postictal fndings help diferentiate LQTS-associated syncope from seizures. Te number of syncopal events in symptomatic individuals ranges from one to hundreds, averaging just a few. In some instances, TdP degenerates to ventricular fbrillation and aborted cardiac arrest (if the individual is defbrillated) or sudden death. \nCardiac events (i.e., syncope, cardiac arrest, or sudden cardiac death) may occur from infancy through middle age but are most common from the preteen years through the 20s, with the risk generally diminishing throughout that time period. Te usual age range of events difers somewhat for each genotype. Cardiac events are uncommon afer age 40 years; when present, they are ofen triggered by administration of a QT-prolonging drug or hypokalemia. Cardiac events in individuals over age 40 years are more likely associated with SCN5Arelated LQTS. \n",
      "token_count": 479,
      "sentence_count": 16
    },
    {
      "id": "arvd_txt_6",
      "contents": "\u2022 Minor \u26ac Late potential by signal-averaged EKG in at least one of three parameters in the absence of a QRS duration of ${\\geq}110~\\mathrm{ms}$ on standard EKG \u26ac Filtered QRS duration $(\\mathrm{fQRS})\\,{\\geq}114\\,\\mathrm{ms}$ $^\\circ$ Duration of terminal QRS ${<}40\\,\\mathrm{uV}$ (low-amplitude signal duration) ${\\geq}38$ ms \u26ac Root-mean-square voltage of terminal $40\\;\\mathrm{ms}\\leq20\\;\\mathrm{uV}$ \n\u26ac Terminal activation duration of $\\mathrm{QRS}>55~\\mathrm{ms}$ measured from the nadir of the S wave to the end of the QRS, including $\\mathrm{R}^{\\prime}$ , in V1, V2, or V3 in the absence of complete right bundle branch block \nArrhythmias \n\u2022 Major. Nonsustained or sustained ventricular tachycardia of lef bundle branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)   \n\u2022 Minor \u26ac Nonsustained or sustained ventricular tachycardia of RV outfow confguration, lef bundle branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis \u26ac ${>}500$ ventricular extrasystoles per 24 hours (Holter) \nFamily History and Molecular Genetic Testing \nMajor \n\u2022 ARVC confrmed in a frst-degree relative who meets 2010 Task Force Criteria [Marcus et al 2010] \u2022 ARVC confrmed pathologically at autopsy or surgery in a frst-degree relative \u2022 Identifcation of a pathogenic variant categorized as associated or probably associated with ARVC in the proband \nMinor \n",
      "token_count": 433,
      "sentence_count": 6
    },
    {
      "id": "arvd_txt_1",
      "contents": "Note: Tere is a movement within clinical cardiology to merge ARVC with other arrhythmogenic cardiomyopathies because the lef ventricle can become involved, or even become predominantly involved, especially in individuals with $D S P$ pathogenic variants; lef ventricular involvement has also been reported in individuals with variants in genes encoding other desmosomal proteins (e.g., DSC2) that were previously associated with ARVC. Te 2010 Task Force Criteria (see Diagnosis) are still used to establish a clinical diagnosis of ARVC [Marcus et al 2010], and these criteria do not incorporate other arrhythmogenic cardiomyopathies, leading to potential underdiagnosis. An international expert panel convened to reevaluate the diagnostic approach to arrhythmogenic cardiomyopathies and developed new criteria, the Padua Criteria [Corrado et al 2020]. Tere are ongoing studies to evaluate the proposed Padua Criteria in larger cohorts. Readers should be aware of the potential overlap/diferentiation between ARVC and other arrhythmogenic cardiomyopathies. \ndescribed stages of ARVC are the following [Te Riele et al 20 \n1. Te concealed phase is the earliest phase and is without electrical, structural, or histologic changes as typically seen in ARVC. If scar formation is present, it can be so minimal that it goes undetected by cardiac MRI. However, afected individuals might experience sustained ventricular arrhythmias, and there is a potential risk of sudden cardiac death.   \n2. An overt electrical disorder characterized by symptomatic arrhythmias including palpitations, syncope, and presyncope attributable to ventricular ectopy or sustained or nonsustained ventricular tachycardia   \n3. Right ventricular failure   \n4. A biventricular pump failure (resembling dilated cardiomyopathy) [Dalal et al 2006] \nCardiomyopathy in ARVC is not always isolatedto right ventricular involvement. Tere is evidence that the  lef ventricle can ofen become involved as well.",
      "token_count": 454,
      "sentence_count": 15
    },
    {
      "id": "hyper-card_txt_20",
      "contents": " Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy. Genet Med. 2013;15:972-7. PubMed PMID: 23598715.   \nLorenzini M, Norrish G, Field E, Ochoa JP, Cicerchia M, Akhtar MM, Syrris P, Lopes LR, Kaski JP, Elliott PM. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020;76:550-9. PubMed PMID: 32731933.   \nMaron BJ (2003) Sudden death in young athletes. N Engl J Med 349:1064-75 PubMed PMID: 12968091.   \nMaron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102:858-64. PubMed PMID: 10952953.   \nMaron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Efect of  lef ventricular outfow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-303 PubMed PMID: 12540642.   \nNagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, Roberts R, Marian AJ (2001) Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 104:128-30 PubMed PMID: 11447072.   \nNiimura H, Patton KK, McKenna WJ, Soults J, Maron BJ, Seidman JG, Seidman CE (2002) Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation 105:446-51 PubMed PMID: 11815426.   \n",
      "token_count": 486,
      "sentence_count": 19
    },
    {
      "id": "dbmd_txt_2",
      "contents": "Evaluation of relatives at risk: Early identifcation of heterozygous females who are at increased risk for cardiomyopathy and, thus, need routine cardiac surveillance and prompt treatment. \nGenetic counseling \nTe dystrophinopathies are inherited in an X-linked manner. Te risk to the sibs of a proband depends on the genetic status of the mother. Heterozygous females have a $50\\%$ chance of transmitting the DMD pathogenic variant in each pregnancy. Sons who inherit the pathogenic variant will be afected; daughters who inherit the pathogenic variant are heterozygous and may have a range of clinical manifestations. Males with DMD usually do not reproduce. Males with BMD or DMD-associated DCM may reproduce: all of their daughters are heterozygotes; none of their sons inherit their father's DMD pathogenic variant. Carrier testing for at-risk females, prenatal testing, and preimplantation genetic testing are possible if the DMD pathogenic variant in the family is known. \nGeneReview Scope \nDystrophinopathies: Included Phenotypes\u00a01 \nDuchenne muscular dystrophy (DMD) Becker muscular dystrophy (BMD) DMD-associated dilated cardiomyopathy \nFor synonyms and outdated names see Nomenclature.   \n1. For other genetic causes of these phenotypes see Diferential Diagnosis. \nDiagnosis \nTe dystrophinopathies cover a spectrum of X-linked muscle disease that ranges from mild to severe and includes Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy (DCM). \nSuggestive Findings \nA dystrophinopathy should be suspected in an individual with the following clinical and laboratory test fndin gs that support the diagnosis of DMD, BMD, or DMD-associated DCM \u2013 especially when they occur in addition to a positive family history compatible with X-linked inheritance. Findings are most commonly noted in males, but females may also be afected. \nClinical Findings \nDuchenne muscular dystrophy (DMD) \n\u2022 Progressive symmetric muscle weakness (proximal $>$ distal) ofen with calf hypertrophy   \n",
      "token_count": 484,
      "sentence_count": 21
    },
    {
      "id": "arvd_txt_5",
      "contents": "100\\,\\mathrm{mL}/\\mathrm{m}^{2}$ to $<\\!110\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (male) or $\\geq\\!90\\;\\mathrm{mL}/\\mathrm{m}^{2}$ to ${<}100\\;\\mathrm{mL}/\\mathrm{m}^{2}$ (female) \u25aa RV ejection fraction ${>}40\\%$ to ${\\le}45\\%$ \nEndomyocardial Biopsy or Autopsy Findings \nMajor. Residual myocytes ${<}60\\%$ by morphometric analysis (or ${<}50\\%$ if estimated), with fbrous replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nMinor. Residual myocytes $60\\%-75\\%$ by morphometric analysis (or $50\\%{-}65\\%$ if estimated), with fbrou s replacement of the RV free wall myocardium in at least one sample, with or without fatty replacement of tissue \nEKG Findings \nRepolarization abnormalities \n\u2022 Major. Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals age ${>}14$ years (in the absence of complete right bundle branch block $\\mathrm{QRS}\\,{\\geq}120~\\mathrm{ms})$ \n\u2022 Minor \u26ac Inverted T waves in leads V1 and V2 in individuals age ${>}14$ years (in absence of complete right bundle branch block) or in V4, V5, or V6 \u26ac Inverted T waves in leads V1, V2, V3, and V4 in individuals age ${>}14$ years in the presence of complete right bundle branch block \nDepolarization/conduction abnormalities \n\u2022 Major. Epsilon waves (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)   \n",
      "token_count": 468,
      "sentence_count": 12
    },
    {
      "id": "brugada_txt_14",
      "contents": "\u2022 EKG changes have low sensitivity in establishing the diagnosis [Corcia 2022]; \u2022 Identifcation of individuals at risk allows preventive measures such as fever control and avoidance of medications that can induce ventricular arrhythmias; Cardiac surveillance can be limited to family members who have the familial Brugada syndrome-related pathogenic variant [Benito et al 2009, Esc\u00e1rcega et al 2009, Nunn et al 2010]. \nIndividuals with a known pathogenic variant should undergo EKG monitoring every one to two years beginning at birth (see Surveillance). \nIf the pathogenic variant has not been identifed in the family, relatives should undergo EKG monitoring every one to two years beginning at birth (see Surveillance). If a type I EKG is identifed, further investigation is warranted. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nHormonal changes during pregnancy can precipitate arrhythmic events in women with Brugada syndrome. Recurrent ventricular tachyarrhythmia can be inhibited, and the electrocardiographic pattern can normalize following IV infusion of low-dose isoproterenol followed by oral quinidine [Sharif-Kazemi et al 2011]. \nQuinidine is not known to be teratogenic to the developing fetus and is a preferred drug to treat arrhythmia in pregnancy. See MotherToBaby for more information about medication use during pregnancy. \nTherapies Under Investigation \nSearch ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: Tere may not be clinical trials for this disorder. \nGenetic Counseling \nGenetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \n",
      "token_count": 470,
      "sentence_count": 18
    },
    {
      "id": "hos_txt_10",
      "contents": "Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions.  Te following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. \u2014ED. \nMode of Inheritance \nHolt-Oram syndrome (HOS) is inherited in an autosomal dominant manner. \nRisk to Family Members \nParents of a proband \n\u2022 Some individuals diagnosed with HOS have an afected parent.   \n\u2022 A proband with HOS ofen has the disorder as the result of a heterozygous de novo TBX5 pathogenic variant. Up to $85\\%$ of cases are caused by a de novo pathogenic variant [Elek et al 1991], while approximately $15\\%$ of cases are familial [Barisic et al 2014].   \n\u2022 Recommendations for the evaluation of parents of a proband with an apparent heterozygous de novo pathogenic variant include echocardiography, EKG, and hand x-rays (anterior/posterior view) to determine their afected status. Alternatively, molecular genetic testing can be performed on the parents if the TBX5 pathogenic variant in the proband has been identifed.   \n\u2022 If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, possible explanations include a de novo pathogenic variant in the proband or germline mosaicism in a parent. Presumed parental germline mosaicism has been reported [Braulke et al 1991].   \n\u2022 Te family history of some individuals diagnosed with HOS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disorder in the afected parent. Terefore, an apparently negative family history cannot be confrmed unless appropriate clinical evaluation and/or molecular genetic testing has been performed on the parents of the proband.   \n\u2022 Note: If the parent is the individual in whom the pathogenic variant frst occurred, the parent may be mildly/minimally afected. \n\nSibs of a proband.",
      "token_count": 489,
      "sentence_count": 17
    },
    {
      "id": "A_Guide_To_Marfan_Syndrome_and_Related_Disorders_txt_3",
      "contents": " Other people have a spontaneous mutation, meaning that they are the first person in their family to have Marfan syndrome. People with Marfan syndrome have a $50\\%$ chance of passing the mutation on each time they have a child. \nPeople are born with Marfan syndrome but may not notice any features until later in life. Marfan syndrome features can appear at any age, including in infants and young children. They often get worse as people age. \n3. WHAT IS THE PROGNOSIS FOR PEOPLE WITH MARFAN SYNDROME? \nThere is no cure for Marfan syndrome, but with early diagnosis, proper treatment and careful management of the disorder, it is possible for people to live a normal life span. The outlook today for people with Marfan syndrome is far brighter than it was a few decades ago. In the days before open-heart surgery, the average life expectancy was reduced by a third. Now, early diagnosis and careful management have greatly improved the prognosis and increased life expectancy. Medical and surgical treatments continue to improve and offer hope to even the most severely affected infants, children and adults. In addition, proper management can relieve or prevent many of the complications that interfere with daily activities. \n1.HOW IS MARFAN SYNDROME DIAGNOSED? \nAlthough scientists have determined that Marfan syndrome is caused by a variation in the fibrillin-1 gene on chromosome 15, there is no simple test that can conclusively diagnose Marfan syndrome. Therefore, diagnosis is made primarily through a clinical evaluation. Genetic testing may be helpful in some situations (see page 22). \nBecause most features of Marfan syndrome progress with age, the diagnosis is often more obvious in teens or adults. But children, even newborns, can and should be examined. For these reasons, the diagnostic evaluation should be performed by physicians experienced with the condition. The evaluation should include: \nA detailed medical and family history.   \nA complete physical examination.   \nA thorough eye examination by an eye specialist (ophthalmologist) using a slit lamp to look for lens dislocation after fully dilating the pupil.   \nAn electrocardiogram (EKG) and an echocardiogram to look for involvement of the cardiovascular system that may be not evident from the physical examination. \n",
      "token_count": 453,
      "sentence_count": 24
    },
    {
      "id": "dcm-lmna_txt_9",
      "contents": "DCM-associated genes have been observed in individuals with nonsyndromic DCM [Morales et al 2020] and because families may segregate pathogenic variants in more than one DCM-related gene [Liu et al 2015, Cowan et al 2018], thorough individualized risk assessment through clinical, genetic, and family history analysis is warranted to determine if discharge from high-risk cardiac surveillance is appropriate. \nIf molecular genetic testing is not possible, the frst-degree relatives of a proband with LMNA-related DCM should be evaluated annually by medical history, physical examination, echocardiogram, and EKG to determine if any have detectable DCM and/or conduction system disease. \nNote: Because the age of onset is variable and penetrance is reduced, a normal baseline echocardiogram and EKG in a frst-degree relative who has not undergone molecular genetic testing does not rule out LMNA-related DCM in that individual, and the recommendations set forth in Surveillance should be followed. \nAny abnormal cardiovascular test results in a relative of a proband with a known LMNA pathogenic variant should be followed up with a full cardiovascular assessment to evaluate for any acquired causes of disease (e.g., coronary artery disease). Results on screening tests that do not meet criteria for DCM but do show some abnormality (e.g., lef ventricular enlargement but normal function; decreased ejection fraction but normal-sized lef ventricle) may refect variable expression of LMNA-related DCM in that relative. Targeted genetic testing to clarify the diagnosis as well as close surveillance (e.g., cardiovascular testing every 1-2 years) for progression of cardiovascular disease is recommended for such individuals. \nSee Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes. \nPregnancy Management \nPregnancy is contraindicated in women with DCM because of the signifcantly increased mortality with pregnancy in DCM. Women with DCM who become pregnant should be followed by a high-risk obstetrician. At-risk women with unknown genetic status should undergo a cardiovascular evaluation and be ofered genetic counseling prior to pregnancy. \nTherapies Under Investigation \n",
      "token_count": 461,
      "sentence_count": 15
    },
    {
      "id": "brugada_txt_26",
      "contents": " PubMed PMID: 33221895.   \nCorcia MCG. Brugada syndrome - minimizing overdiagnosis and over treatment in children. Curr Opin Cardiol. 2022;37:80\u20135. PubMed PMID: 34654031.   \nDelise P, Marras E, Bocchino M. Brugada-like electrocardiogram pattern: how to stratify the risk for sudden cardiac death. Is sports activity contraindicated? J Cardiovasc Med (Hagerstown). 2006;7:239\u201345. PubMed PMID: 16645396.   \nde Oliveira Neto NR, de Oliveira WS, Mastrocola F, Sacilotto L. Brugada phenocopy: Mechanisms, diagnosis, and implications. J Electrocardiol. 2019;55:45\u201350. PubMed PMID: 31078108.   \nEastaugh LJ, James PA, Phelan DG, Davis AM. Brugada syndrome caused by a large deletion in SCN5A only detected by multiplex ligation-dependent probe amplifcation. J Cardiovasc Electrophysiol. 2011;22:1073\u20136. PubMed PMID: 21288276.   \nEckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, Wichter T, Boisseau P, Heinecke A, Breithardt G, Borggrefe M, LeMarec H, Bocker D, Wilde AA. Long-term prognosis of individuals with right precordial STsegment-elevation Brugada syndrome. Circulation. 2005;111:257\u201363. PubMed PMID: 15642768.   \nEsc\u00e1rcega RO, Jim\u00e9nez-Hern\u00e1ndez M, Garcia-Carrasco M, Perez-Alva JC, Brugada J. Te Brugada syndrome. Acta Cardiol. 2009;64:795\u2013801. PubMed PMID: 20128157.   \n",
      "token_count": 434,
      "sentence_count": 31
    },
    {
      "id": "dcm-lmna_txt_1",
      "contents": " Cardiac transplantation or other advanced therapies may be considered for refractory disease in persons receiving comprehensive care from cardiovascular disease experts. \nSurveillance: Individuals with an LMNA pathogenic variant who are found to have any EKG abnormality should undergo a cardiovascular evaluation for disease progression (EKG, 24-48 hour rhythm monitoring, LV function measurement) at least annually. Asymptomatic individuals with a pathogenic LMNA variant should undergo cardiovascular evaluation (medical history, physical examination, echocardiogram, and EKG) every one to two years and/or whenever new symptoms arise. In families with a known LMNA pathogenic variant, at-risk individuals for whom genetic testing is not possible should have yearly cardiovascular evaluation. At onset of new symptoms an immediate evaluation for evidence of DCM and/or conduction system disease is indicated regardless of genetic status. \nEvaluation of relatives at risk: To facilitate prompt diagnosis, targeted LMNA genetic testing when the familyspecifc pathogenic variant is known; otherwise regular surveillance with cardiovascular screening tests. \nPregnancy management: Pregnancy is contraindicated in women with DCM. Pregnant women with DCM should be followed by a high-risk obstetrician. At-risk women with unknown genetic status should undergo a cardiovascular evaluation and be ofered genetic counseling, ideally prior to pregnancy. \nGenetic counseling \nLMNA-related DCM is inherited in an autosomal dominant manner. Some individuals diagnosed with LMNArelated DCM have an afected parent; the proportion of individuals with LMNA-related DCM caused by a de novo pathogenic variant is unknown. Each child of an individual with LMNA-related DCM has a $50\\%$ chance of inheriting the pathogenic variant. Once an LMNA pathogenic variant has been identifed in an afected family member, prenatal testing and preimplantation genetic testing are possible. \nDiagnosis \nSuggestive Findings \nLMNA-related dilated cardiomyopathy (DCM) should be considered in individuals with the following clinical fndings and family history. \nClinical fndings \n",
      "token_count": 438,
      "sentence_count": 17
    },
    {
      "id": "brugada_txt_5",
      "contents": " Sequence analysis of the gene of interest is performed frst, followed by genetargeted deletion/duplication analysis if no pathogenic variant is found. \n\nA multigene panel that includes the genes listed in Table 1 and other genes of interest (see Diferenti al Diagnosis) may also be considered to identify the genetic cause of the condition while limiting identifcation of variants of uncertain signifcance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) Te genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specifed by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. \nFor an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here. \nOption 2 \nComprehensive genomic testing does not require the clinician to determine which gene is likely involved.   \nExome sequencing is most commonly used; genome sequencing is also possible. \nFor an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here. \nAAD: antiarrhythmic drugs   \nANS: autonomic nervous system   \nARVC/D: arrhythmogenic right ventricular cardiomyopathy/dysplasia   \nBS: Bpugada syndrome   \nCNS: central nervous system   \nECG: elecrocardiogram   \nLVH: left ventricularhypertrophy   \nMl: myocardial infarction   \nPVT: polymorphicventricular tachycardia   \nRBBB: right ventricular bundle branch block   \nRVMI: right ventricular myocardial infarction   \nRVOT: right ventricular outflow tract   \nSCD: sudden cardiac death   \nVF: ventricular fibrillation \nReproduced from Berne & Brugada [2012] with permission \n1. See Table A.",
      "token_count": 476,
      "sentence_count": 28
    },
    {
      "id": "brugada_txt_1",
      "contents": "Brugada syndrome is characterized by cardiac conduction abnormalities (ST segment abnormalities in leads $\\mathrm{V}_{1}$ - $\\mathrm{V}_{3}$ on EKG and a high risk for ventricular arrhythmias) that can result in sudden death. Brugada syndrome presents primarily during adulthood, although age at diagnosis may range from infancy to late adulthood.  Te mean age of sudden death is approximately 40 years. Clinical presentations may also include sudden infant death syndrome (SIDS; death of a child during the frst year of life without an identifable cause) and sudden unexpected nocturnal death syndrome (SUNDS), a typical presentation in individuals from Southeast Asia. Other conduction defects can include frst-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome. \nDiagnosis/testing \nTe diagnosis of Brugada syndrome is established clinically in an individual with characteristic EKG fndin gs and suggestive clinical history and/or family history. A molecular diagnosis can be established in an individual with characteristic features and identifcation of a heterozygous pathogenic variant in SCN5A or one of the additional 42 genes associated with Brugada syndrome. \nManagement \nTreatment of manifestations: Implantable cardioverter defbrillator (ICD) in individuals with a history of syncope or cardiac arrest; isoproterenol for electrical storms. During surgery and in the postsurgical recovery period persons with Brugada syndrome should be monitored by EKG. \nPrevention of primary manifestations: Quinidine ( $1{\\mathrm{-}}2\\ {\\mathrm{g}}$ daily). Treatment of asymptomatic individuals is controversial. \nSurveillance: EKG monitoring every one to two years for at-risk individuals with a family history of Brugada syndrome or who have a known pathogenic variant that can lead to Brugada syndrome. \n",
      "token_count": 414,
      "sentence_count": 13
    },
    {
      "id": "jln_txt_0",
      "contents": "Jervell and Lange-Nielsen Syndrome \nSynonym: JLNS   \nLisbeth Tranebj\u00e6rg, MD, PhD, $^{1,2}$ Ricardo A Samson, MD,3 and Glenn Edward Green, MD4   \nCreated: July 29, 2002; Updated: August 17, 2017. \nSummary \nClinical characteristics \n",
      "token_count": 66,
      "sentence_count": 5
    },
    {
      "id": "thompson_thompson_genetics_8th_edition_medicoscompanion_com_txt_767",
      "contents": "LQT syndrome is caused by repolarization defects in cardiac cells. Repolarization is a controlled process that requires a balance between inward currents of sodium and calcium and outward currents of potassium. Imbalances cause the action potential of cells to increase or decrease in duration, causing elongation or shortening, respectively, of the QT interval on electrocardiography. Most cases of LQT syndrome are caused by loss-of-function mutations in genes that encode subunits or regulatory proteins for potassium channels (genes whose names begin with KCN). These mutations decrease the outward, repolarization current, thereby prolonging the action potential of the cell and lowering the threshold for another depolarization. In other LQT syndrome patients, gain-of-function mutations in a sodium channel gene, SCN5A, lead to an increased influx of sodium, resulting in similar shifting of action potential and repolarization effects. \nPhenotype and Natural History \nThe LQT syndromes are characterized by elongated QT interval and T-wave abnormalities on electrocardiography (Fig. C-28), including tachyarrhythmia and torsades de pointes, a ventricular tachycardia characterized by a change in amplitude and twisting of the QRS complex. Torsades de pointes is associated with a prolonged QT interval and typically stops spontaneously but may persist and worsen to ventricular fibrillation. \n\nIn the most common LQT syndrome, Romano-Ward, syncope due to cardiac arrhythmia is the most frequent symptom; if undiagnosed or left untreated, it recurs and can be fatal in $10\\%$ to $\\bar{1}5\\%$ of cases. However, between $30\\%$ and $50\\%$ of individuals with the syndrome never show syncopal symptoms. Cardiac episodes are most frequent from the preteen years through the 20s, with the risk decreasing over time. Episodes may occur at any age when triggered by QTprolonging medications (see list at http://www.qtdrugs.org). Nonpharmacological triggers for cardiac events in the Romano-Ward syndrome differ on the basis of the gene responsible. LQT1 triggers are typically adrenergic stimuli, including exercise and sudden emotion.",
      "token_count": 492,
      "sentence_count": 16
    },
    {
      "id": "dcm-lmna_txt_2",
      "contents": "\u2022 A clinical diagnosis of idiopathic DCM (etiology not attributed to coronary artery disease, structural heart disease, or other established clinical conditions that may cause DCM; see Dilated Cardiomyopathy Overview), almost always in the setting of conduction system disease and/or supraventricular or ventricular arrhythmias. Te diagnosis of DCM is based on the principal fndings of lef ventricular enlargement and/or reduced systolic function (other causes excluded): \u26ac Lef ventricular enlargement is most commonly identifed with two-dimensional echocardiography, optimally assessed by a height- and sex-based approach [Vasan et al 1997], or by cardiac magnetic resonance (CMR) imaging. \u26ac Reduced systolic function is described clinically as a reduction in lef ventricular ejection fraction, which can be measured by two-dimensional echocardiography, angiography, radioisotope scanning, or MRI of lef ventricular function. An ejection fraction of less than $50\\%$ is considered systolic dysfunction [Bozkurt et al 2021].   \n\u2022 Te key distinguishing characteristic of LMNA-related DCM is that conduction system disease and/or arrhythmias almost always occur prior to or in association with the evolution of DCM and commonly before the development of heart failure (see Clinical Description). \nFamily history is consistent with autosomal dominant inheritance (e.g., afected males and females in multiple generations). A detailed three- to four-generation family history looking for heart failure, DCM, cardiac transplantation, pacemakers or implantable cardiac defbrillators, unexplained sudden death, unexplained \ncardiac conduction system disease and/or arrhythmia, or unexplained stroke or other thromboembolic disease in relatives is indicated to assess the possibility of LMNA-related DCM. Conduction system disease, particularly with pacemakers, is particularly suggestive of LMNA-related DCM. \nEstablishing the Diagnosis \nTe diagnosis of LMNA-related DCM is established in a proband with suggestive fndings and a heterozygous pathogenic variant in LMNA identifed on molecular genetic testing (see Table 1). \n",
      "token_count": 500,
      "sentence_count": 12
    }
  ],
  "scan_analyses": [
    {
      "scan_type": "ECG",
      "scan_date": "2025-03-25T09:09:28.833517",
      "file_name": "norm.png",
      "description": "ECG Scan for Patient",
      "analysis": "Okay, let's analyze this ECG tracing. Here\u2019s a detailed breakdown of what I observe, considering it's an ECG scan for a patient:\n\n**Overall Impression:**\n\nThis ECG shows a sinus rhythm, but with several concerning features that warrant careful attention. The primary concern is the presence of significant left ventricular hypertrophy (LVH). \n\n**Detailed Observations:**\n\n1. **Rate:** The heart rate appears to be approximately 75-80 beats per minute. It's regular, which is good.\n\n2. **Rhythm:** The rhythm is sinus rhythm \u2013 the P waves appear to be originating from the sinoatrial node, the heart\u2019s natural pacemaker.\n\n3. **P Waves:** \n   *  Generally, P waves are upright in leads I, II, aVF, and V1-V3, indicating normal atrial depolarization. \n   *  However, they are slightly bizarre and not perfectly consistent in morphology.\n\n4. **PR Interval:** The PR intervals are generally within the normal range (0.12-0.20 seconds). \n\n5. **QRS Complex:** This is where the most significant abnormalities are observed.\n   * **Width:** The QRS complexes are wide \u2013 consistently greater than 0.12 seconds. This is a key indicator of intraventricular conduction delay.\n   * **Morphology:** The QRS complexes are notched, particularly in V1, V3, V5, and V6. This suggests a ventricular depolarization abnormality, possibly due to the LVH. The R waves are also prominent and elevated, further supporting this.\n\n6. **ST Segment & T Waves:**\n   * **ST Segment:** The ST segments are generally isoelectric (flat) except for a slight depression in leads V4-V6. This could represent early signs of ischemia or myocardial strain, but needs further investigation.\n   * **T Waves:** The T waves are predominantly negative, which is a common finding in LVH.\n\n7. **Axis:** The QRS axis appears to be shifted to the left (approximately -45\u00b0 to -60\u00b0), which is consistent with LVH.\n\n8. **Intervals:**\n   * **QT Interval:** The QT interval is within the normal range.\n\n**Significant Findings & Potential Abnormalities:**\n\n* **Left Ventricular Hypertrophy (LVH):** This is the most prominent finding. The wide QRS complexes, prominent"
    }
  ],
  "medical_entities": {
    "HISTORY": [
      "-02-16",
      "illness"
    ],
    "SIGN_SYMPTOM": [
      "headache",
      "P waves",
      "depolarization",
      "intraventricular conduction delay",
      "depression",
      "Left Ventricular"
    ],
    "DIAGNOSTIC_PROCEDURE": [
      "physical exam",
      "assessment",
      "ECG",
      "heart rate",
      "Rhythm",
      "rhythm",
      "P Waves",
      "P waves",
      "leads",
      "atrial",
      "PR Interval",
      "PR intervals",
      "QRS Complex",
      "QRS complexes",
      "R waves",
      "ST Segment",
      "T Waves",
      "ST segments",
      "T waves",
      "Axis",
      "QRS axis",
      "Intervals",
      "QT Interval",
      "QT interval"
    ],
    "DATE": [
      "03",
      "25",
      "09:09:28.833"
    ],
    "LAB_VALUE": [
      "sinus rhythm",
      "75-80 beats per minute",
      "regular",
      "upright",
      "normal",
      "slightly bizarre",
      "not",
      "consistent",
      "within the normal range",
      "0.12-0.20 seconds",
      "wide",
      "greater than 0.12 seconds",
      "notched",
      "prominent",
      "elevated",
      "isoelectric",
      "flat",
      "negative",
      "shifted to the left",
      "-45\u00b0 to -60\u00b0",
      "within",
      "normal range"
    ],
    "SEVERITY": [
      "significant"
    ],
    "DISEASE_DISORDER": [
      "left ventricular hypertrophy",
      "LVH",
      "ventricular depolarization abnormality",
      "ischemia",
      "myocardial strain",
      "Hypertrophy",
      "H"
    ],
    "BIOLOGICAL_STRUCTURE": [
      "sinoatrial node",
      "V1, V3",
      "V5",
      "and V6"
    ],
    "DETAILED_DESCRIPTION": [
      "natural pacemaker",
      "I, II, aVF, and V1-V3",
      ",",
      "V4-V6"
    ]
  },
  "analysis_date": "2025-03-25T14:28:41.321001",
  "created_at": "2025-03-25T14:28:41.321005"
}